About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

Active Not RecruitingPhase 3NCT03519230

Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer

To evaluate the efficacy, safety and tolerability of maintenance therapy with BGB-290(Pamiparib) versus placebo in Chinese participants with recurrent ovarian cancer who achieved a complete response (...

Lead sponsor: BeiGene•28 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Start Free Trial

Sponsors

Lead Sponsor

BeiGene

Age

18 - No limit years

Sex

FEMALE

Healthy Volunteers

No

Inclusion Criteria

•1. Histologically diagnosed high-grade serous or endometrioid ovarian cancer (including primary peritoneal and fallopian tube cancer)
•2. Completion of ≥2 previous platinum-containing regimens (eg, carboplatin or cisplatin)
•3. Complete response (CR) or partial response (PR) achieved with last platinum-based chemotherapy regimen as determined by investigator per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
•4. Ability to be randomized ≤8 weeks after last dose of platinum

Exclusion Criteria

•1. Prior treatment with a poly (ADP-ribose) polymerase (PARP) inhibitor
•2. Progressive disease (PD) as per CA-125 criteria before randomization
•3. Diagnosis of myelodysplastic syndrome (MDS)
•4. Known history of intolerance to the excipients of the Pamiparib capsule

Related studies

Familial Investigations of Childhood Cancer Predisposition

NCT03050268 · Acute Leukemia, Adenomatous Polyposis, and more

RECRUITINGPhase 1

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

NCT06257264 · Breast Cancer, Small Cell Lung Cancer, and more

RECRUITINGPhase 1

DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer

NCT06964009 · Ovarian Cancer, Ovarian Carcinoma, and more

Use of the CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women

NCT00539162 · Ovarian Cancer

RECRUITINGPhase 3

Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

NCT06915025 · Epithelial Ovarian Cancer, Ovarian Cancer, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: March 16, 2026Terms

Trial snapshot

StatusACTIVE_NOT_RECRUITING

PhasePHASE3

Enrollment224

Start dateMay 2018

Last updatedMar 16, 2026

Condition

Locations shown

Anhui Provincial Cancer Hospital Aka West Branch of Anhui Province Hospital

Hefei, Anhui

Peking University First Hospital

Beijing, Beijing Municipality

Beijing Cancer Hospital

Beijing, Beijing Municipality

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 16, 2026Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions